Spyre Therapeutics (NASDAQ:SYRE) Releases Earnings Results

Posted by Geri Gentry on Nov 3rd, 2026

Spyre Therapeutics (NASDAQ:SYRE – Get Free Report) announced its earnings results on Tuesday. The company reported ($0.94) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.79) by ($0.15), FiscalAI reports.

Spyre Therapeutics Trading Up 3.9%

Shares of NASDAQ:SYRE traded up $3.76 on Tuesday, hitting $99.27. The company had a trading volume of 902,874 shares, compared to its average volume of 1,125,618. The stock has a market cap of $10.12 billion, a price-to-earnings ratio of -50.91 and a beta of 3.10. The stock has a 50 day moving average price of $89.84 and a 200 day moving average price of $73.17. Spyre Therapeutics has a 1-year low of $21.15 and a 1-year high of $110.18.

Insider Activity at Spyre Therapeutics

In other Spyre Therapeutics news, insider Heidy King-Jones sold 28,933 shares of the stock in a transaction dated Thursday, October 1st. The shares were sold at an average price of $91.03, for a total value of $2,633,770.99. Following the transaction, the insider directly owned 2,845 shares of the company’s stock, valued at $258,980.35. This represents a 91.05% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Scott L. Burrows sold 7,500 shares of the firm’s stock in a transaction that occurred on Thursday, October 1st. The stock was sold at an average price of $91.83, for a total transaction of $688,725.00. Following the sale, the chief financial officer owned 79,762 shares of the company’s stock, valued at $7,324,544.46. This trade represents a 8.59% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last quarter, insiders have sold 161,064 shares of company stock worth $14,753,768. 15.69% of the stock is owned by corporate insiders.

Analyst Ratings Changes

SYRE has been the topic of several research analyst reports. Wall Street Zen downgraded Spyre Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday. UBS Group began coverage on Spyre Therapeutics in a report on Sunday, October 11th. They issued a “buy” rating and a $120.00 price target for the company. Guggenheim raised their price target on Spyre Therapeutics from $115.00 to $130.00 and gave the stock a “buy” rating in a research report on Wednesday, August 5th. Wedbush reiterated an “outperform” rating and issued a $123.00 price objective on shares of Spyre Therapeutics in a research report on Wednesday, September 9th. Finally, Mizuho boosted their price objective on Spyre Therapeutics from $84.00 to $120.00 and gave the company an “outperform” rating in a research report on Monday, July 13th. Two analysts have rated the stock with a Strong Buy rating, thirteen have given a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $110.40.

Check Out Our Latest Research Report on Spyre Therapeutics

About Spyre Therapeutics

(Get Free Report)

Spyre Therapeutics, Inc is a clinical-stage biotechnology company focused on developing next-generation treatments for inflammatory bowel disease (IBD), including Crohn’s disease and ulcerative colitis. The company’s approach is centered on engineered antibody therapies designed to provide durable disease control, convenient dosing and improved treatment characteristics.

Spyre’s investigational pipeline includes antibody programs directed at important inflammatory pathways, including interleukin-23 (IL-23) and TL1A.